CD274 and non-small cell lung carcinoma: In the open-label phase III IMpower 131 and IMpower 150 trials, including patients with squamous and nonsquamous advanced NSCLC respectively and any PD-L1 expression, the combinations of atezolizumab plus carboplatin and nab-paclitaxel (IMpower 131) or plus carboplatin, paclitaxel and bevacizumab (IMpower 150) were related to better PFS than chemotherapy or chemotherapy plus bevacizumab alone.